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Dear Editor,
The use of novel therapies, such as immunomodulatory
drugs (IMiDs), proteasome inhibitors (PIs), and mono-
clonal antibodies (mAbs; ie, isatuximab, daratumumab,
elotuzumab), has significantly improved the outcomes of
multiple myeloma (MM) patients. However, MM remains
largely incurable, with the majority of patients becoming
refractory to available therapies and eventually relapsing.
Isatuximab binds to a specific epitope on CD38 and
selectively induces MM cell death through several
mechanisms, including antibody-dependent cell-mediated
cytotoxicity, antibody-dependent cellular phagocytosis, and
complement-dependent cytotoxicity1. Isatuximab is the
only anti-CD38 mAb that induces direct apoptosis in MM
cell lines in the absence of cross-linking agents and inde-
pendently of effector cells2,3. Additionally, isatuximab
inhibits CD38 enzymatic activity more effectively than
daratumumab3, resulting in decreased adenosine produc-
tion, and may alleviate the immunosuppressive micro-
environment of the bone marrow niche in MM patients4.
Isatuximab also induces indirect antitumor activity through
the elimination of CD38+ immunosuppressive regulatory
T cells and through an “in vivo vaccination” effect
(reviewed by Martin et al.4). Isatuximab is approved in
combination with pomalidomide and dexamethasone (Pd)
in the USA, Europe, and Asia for the treatment of adult
patients with relapsed/refractory MM (RRMM) who have
received at least two prior therapies, including lenalido-
mide and a PI5–7. Daratumumab is a different anti-CD38
mAb and is approved for use in MM as monotherapy and
in combination regimens.
This Phase 1/2 study (ClinicalTrial.gov identifier,
NCT02514668) was conducted in 19 sites in the USA and
Europe. Patients were treated with isatuximab 20 mg/kg
every week for 4 weeks and every other week thereafter.
The safety and efficacy of isatuximab in Part A (Phase 1)
were generally comparable to other isatuximab studies in
MM8,9. This report presents Part B (Phase 2), assessing
the response, safety, pharmacokinetics, and immuno-
genicity of isatuximab in daratumumab-refractory RRMM
patients.
The objective of Part B was to assess the clinical benefit
of isatuximab monotherapy in daratumumab-refractory
RRMM patients, as measured by overall response rate
(ORR). To our knowledge, this was the first prospective
study evaluating the ability of anti-CD38 mAb mono-
therapy to overcome the refractoriness of of patients to a
different anti-CD38 mAb.
The study design is summarized in Supplementary Fig.
S1. Eligible patients had RRMM and progressed on/after
standard therapy, including an IMiD and a PI, and had (1)
≥3 prior cycles of daratumumab treatment with ≥6 weeks
from the last daratumumab treatment to the first study
treatment or (2) ≥2 cycles of daratumumab treatment if
another therapy was given between daratumumab and
isatuximab, with ≥12 weeks from the last daratumumab
treatment to the first study treatment.
Patient baseline characteristics (N= 32) are shown in
Table 1. Overall, 75% of patients were ≥65 years old and
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34.4% of patients had Eastern Cooperative Oncology
Group stage II or III. One-third (31.3%) had International
Staging System stage III at study entry. High-risk cyto-
genetic status was determined for 13/32 patients based
on ≥1 del17p (3/13 [23.1%] patients) or t(4;14) (3/13
[23.1%] patients) or t(14;16) (0 patients). Patients were
very heavily pretreated, with a median of 7 (range, 2–14)
prior lines; two-thirds of patients (68.8%) received ≥5
prior lines of therapy. All patients were refractory
(showed progression of disease on treatment or within
60 days of treatment end date) to daratumumab alone or
in combination and to their last treatment line. Overall,
75% of patients were double refractory and 28% were
quad- or penta-refractory. Over 50% previously received
daratumumab in combination with other therapies. The
majority of patients (60%) received daratumumab com-
bination therapy just prior to isatuximab treatment,
62.5% had <6 months between last daratumumab and
first isatuximab dose, and 15% received ≥2 prior dar-
atumumab lines.
The median duration of exposure to isatuximab was
8.3 weeks (range, 1–74 weeks; Supplementary Table S1).
Eleven patients received dexamethasone after either the





Median (range) 70.5 (51–84)
<65 years, n (%) 8 (25.0)
65–74 years, n (%) 14 (43.8)
≥75 years, n (%) 10 (31.3)
Median time from diagnosis to first dose,
years (range)
7.1 (1.2–19.4)




Kappa light chain only 6 (18.8)
Lambda light chain only 5 (15.6)
ISS stagea, n (%)
Stage I 12 (37.5)
Stage II 9 (28.1)
Stage III 10 (31.3)
Unknown 1 (3.1)





Cytogenetic riskb, n (%)
High-risk CA 5 (15.6)
Standard-risk CA 8 (25.0)
Unknown or missing 19 (59.4)
Number of prior lines of therapy
Median (range) 7.0 (2–14)
Number of prior lines by patient by category, n (%)
<5 10 (31.3)
≥5 22 (68.8)
Prior therapy, n (%)
Alkylating agent 31 (96.9)
IMiD agent 31 (96.9)
PI agent 32 (100)
PI and IMiD agent 31 (96.9)
Dara 32 (100)
Refractory status, n (%)
IMiD refractory 29 (90.6)
PI refractory 26 (81.3)
PI and IMiD refractory 24 (75.0)
Quad-refractory (RPVK) 9 (28.1)
Penta-refractory (RPVK–Dara) 9 (28.1)
Refractory to last line 32 (100)
Refractory to Dara 32 (100)




Dara therapy type, n (%)
Monotherapy 15 (46.9)




Duration of Dara treatment by category (months), n (%)
<6 months 14 (43.8)
≥6 months 18 (56.3)
Best response with Dara, n (%)
Complete response 3 (9.4)
Very good partial response 7 (21.9)
Partial response 10 (31.3)
Minimal response 2 (6.3)
Stable disease 6 (18.8)
Progressive disease 4 (12.5)
Median time from last dose Dara to first Isa,
weeks (range)
13.07 (6–80.7)
<12 weeks 14 (43.8)
≥12 weeks 18 (56.3)
<24 weeks 20 (62.5)
≥24 weeks 12 (37.5)
<48 weeks 27 (84.4)
≥48 weeks 5 (15.6)
Dara as last line prior to Isa, n (%) 19 (59.4)
CA chromosomal abnormalities, COPD chronic obstructive pulmonary disease, d
dexamethasone, Dara daratumumab, ECOG Eastern Cooperative Oncology
Group, Ig immunoglobulin, IMiD immunomodulatory drug, Isa isatuximab, ISS
International Staging System, K carfilzomib, MM multiple myeloma, P
pomalidomide, PI proteasome inhibitor, QW/Q2W once weekly for 4 weeks,
then every other week, R lenalidomide, V bortezomib.
aISS staging was derived based on the combination of serum β2-microglobulin
and albumin.
bHigh-risk CA was defined as the presence of del(17p), and/or t(4;14), and/or t
(14;16) by fluorescence in situ hybridization. Cytogenetic analysis was performed
by a central laboratory with a cut-off of 10% of analyzed plasma cells for del
(17p), and 15% of analyzed plasma cells for t(4;14) and t(14;16).
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second or the fourth cycle, depending on the observed
response. Two of the 32 enrolled patients were not eva-
luable for response. Objective ORR was not reached
(Supplementary Table S2). One (3.1%) patient had mini-
mal response (MR) and 17 (53.1%) patients had stable
disease (SD). The disease control rate (DCR, defined as
≥MR or SD ≥8 weeks) was 37.5%. A long duration of
treatment and prolonged SD were observed in some
patients (Fig. 1A). One patient had SD and a treatment
duration of 74 weeks (18.5 months), whereas three
patients had a treatment duration of ≥6 months and three
patients of ≥3 months.
Fig. 1 Isatuximab monotherapy treatment response correlation with CD38 receptor density. A Swimmer plot of time on treatment with
isatuximab monotherapy. Each bar represents one of the 31 patients evaluable for response in the study (i.e., patients who completed at least one
cycle of treatment and who had at least one disease assessment or patients with clinical progression or patients who died within 30 days of first dose
due to disease progression). One out of the 31 patients had no evaluable response. Text in red font corresponds to the reason for treatment
discontinuation. B Higher baseline CD38 receptor density was associated with longer periods from the last daratumumab dose to the CD38 receptor
density assessment date. The scatter plot shows the CD38 receptor density data and time from last daratumumab dose to CD38 receptor density
assessment date (all-treated population). The CD38 receptor density of cancer cells was measured at baseline by quantitative flow cytometry in bone
marrow aspirate from 19 of 32 patients. The estimated CD38 receptor density reflects the number of free receptors per cell accessible for isatuximab
binding and not the total CD38 receptor density. BOR best overall response, MRminimal response, NE not evaluable, PD progressive disease, QW/Q2W
once weekly for 4 weeks, then every other week, SD stable disease.
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Importantly, the DCR doubled in patients with the
longest interval between the last daratumumab dose and
the first isatuximab dose; 58.3% with a washout
≥6 months vs 28.6% with a washout <3 months (Supple-
mentary Table S3). DCR was high (72.7%) among the 11
patients who received dexamethasone with isatuximab.
Median progression-free survival was 1.6 months (95%
CI: 1–3.2) and median overall survival was 10.7 months
(95% CI: 8–19, Supplementary Table S2).
Isatuximab and daratumumab pharmacokinetics analyses
are described in the Supplementary Appendix (Fig. S2).
Primary resistance to daratumumab or isatuximab has
been linked to CD38 receptor density (RD) and there is a
trend toward higher response rates with increasing CD38
RD (reviewed by Martin et al.4). Therefore, we measured
the CD38 RD using flow cytometry with an antibody
competing with daratumumab (the estimated CD38 RD
reflects the number of free receptors per cell accessible for
isatuximab binding). Higher baseline CD38 RD was
associated with longer periods from the last daratumumab
dose to the CD38 RD assessment date (Fig. 1B). However,
these data should be interpreted with caution, as the test
did not permit accurate measurement of CD38 RD. Col-
lectively, CD38 RD values from 0 to <5000 RD/cell were
detected in 11 patients who had <20 weeks from last
daratumumab dose to the CD38 RD assessment date. This
may have been due to shedding, aggregation, inter-
nalization, or 100% occupation of CD38 receptors on
bone marrow cells by daratumumab (Fig. 1B). The three
patients with a CD38 RD of ≥150,000/cell had a better
DCR of 66.7% compared with 37.5% for the 16 patients
with a CD38 RD of <150,000/cell. This threshold corre-
sponds to the median value reported in the isatuximab
monotherapy study8.
The safety profile in this study is described in the
Supplementary Appendix and was similar to that reported
in prior isatuximab monotherapy studies8,9, with no new
safety concerns (Supplementary Tables S4 and S5). A total
of 28 (87.5%) and 16 (50.0%) patients had treatment-
emergent adverse events (TEAEs) and a Grade ≥3 TEAE,
respectively. There were very few interrupted infusions (5/
257). Infusion reactions (IR, all Grades 1–2) were reported
in 18.8% of patients. Such lower IR incidence compared
with other isatuximab studies is presumably due to prior
exposure to another anti-CD38 mAb.
This isatuximab monotherapy study included very
heavily pretreated and daratumumab-refractory RRMM
patients, with the majority treated with daratumumab
combination therapy and as last line. Based on its recent
approvals, isatuximab will predominantly be used in clin-
ical practice as combination therapy and in earlier lines,
and results of ongoing clinical trials may shed light on the
effectiveness of isatuximab combination therapy in
daratumumab-refractory RRMM patients. The Phase 1b
Part B study (ClinicalTrials.gov, NCT02283775) of isa-
tuximab combined with Pd administered by a fixed-
volume infusion method enrolled 7 (of 47) RRMM
patients with prior daratumumab exposure. All seven
patients were daratumumab-refractory and none of the
patients received daratumumab as last regimen. At interim
data analysis, six of those seven patients were evaluable for
response and one had partial response, two had MR, and
three had SD10. A real-world analysis of RRMM patients
with prior daratumumab therapy demonstrated that 10/15
patients experienced a response of MR or better with
isatuximab in combination with Pd treatment11. In line
with these observations, a retrospective study showed that
patients refractory to daratumumab and pomalidomide
exhibited an ORR of 33% when retreated with dar-
atumumab combined with Pd, indicating that the combi-
nation of IMiDs may overcome anti-CD38 mAb
refractoriness by increasing plasma cell CD38 expression
and enhancing T-cell and NK-cell responses12.
In conclusion, this cohort of daratumumab-refractory
RRMM patients treated with isatuximab monotherapy was
heavily pretreated, with a median of 7 (range, 2–14) prior
lines and 100% were refractory to daratumumab. The
majority was recently exposed to daratumumab combina-
tion therapy, with ~60% having the last daratumumab dose
within 6 months and as the last line of therapy. Although
there were no objective responses, 1 (3.1%) patient
achieved MR and 17 (53.1%) patients had SD as best overall
response, with the longest duration of SD being
18.5 months. The DCR in this heavily pretreated popula-
tion, refractory to last line and to daratumumab, was 37.5%.
Better responses were observed in patients with longer
intervals (in particular, ≥6 months) from the last dar-
atumumab dose to the first isatuximab dose, as measured
by a higher DCR (26.4% [last dose <6 months] vs 58.3%
[last dose ≥6 months] vs 60.0% [last dose ≥12 months]).
Further study regarding the use of isatuximab post dar-
atumumab, or vice versa, is required to better understand
the optimal timing and sequencing of CD38 mAbs in MM.
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